We established a quick response research team to monitor the impacts of global pandemic COVID19 on this market to keep our clients informed about latest data and changing strategies. The report will incorporate these insight and data factors. ×
Market Research Report

Global Genome Editing/Genome Engineering Market Size, Trends, Share, Market Segmentation By Intended Audience & by Region with Forecast 2017-2030

Published Date :


Report Pages :


Format :


Region Covered :


Global Genome Editing/Genome Engineering Market Overview                          

Using powerful, proven next-generation sequencing (NGS) and microarray solutions, researchers are now able to read and understand genetic variations at new depths, more easily and quickly than before, enabling a wide variety of genomics applications. As a result, discoveries that were unimaginable even a few years ago are becoming routine, for instance, CRISPR-Cas technology have the potential to carry out genome editing functions or alter gene expression for gene silencing, DNA free gene editing, homology-directed repair, transcriptional repression, knockout screening and embryonic stem cell. Currently, The CRISPR system is revolutionizing the way biological researches are conducted and paves a bright future not only in research but also in medicine and biotechnology.  

Goldstein Market Intelligence analyst forecast the Genome Editing/Genome Engineering market size is growing at a CAGR of 13.2% over the forecast years 2017-2030. The major factors propelling the growth of this market are increasing government funding and number of genomics projects, high prevalence of infectious diseases and cancer, technological advancements, increasing production of genetically modified crops, and growing application areas of genomics and proteomics.

Intended Audience

  • In–licensing life sciences companies (pharmaceutical/biopharmaceutical/biotechnology)
  • Out–licensing life science company (pharmaceutical/biopharmaceutical/biotechnology)
  • Genome Editing/Genome Engineering research organizations
  • Academic institutes
  • Government and private research institutes
  • Medical research centers
  • Public and private health agencies
  • Genome Editing/Genome Engineering and biotechnology associations
  • Business consultancies
  • Venture capitalists

Global Genome Editing/Genome Engineering Market Segmentation

By Technology

  • CRISPR (Clustered Regularly Interspersed Short Palindromic Repeats)
  • ZFN
  • Other ((PiggyBac, Flp-In, Adenine Base Editor (ADE), Antisense and Jump-In)

By Application

  • Cell Line Engineering
  • Animal Genetic Engineering
  • Plant Genetic Engineering

By End User

  • Biotechnology & Pharmaceutical Companies
  • CROs

Based on Geography

  • North America (U.S. & Canada)  Genome Editing/Genome Engineering Market {Market Share (%), Market Size (USD Billion)}
  • Latin America (Brazil, Mexico, Argentina & Rest of Latin America)  Genome Editing/Genome Engineering Market {Market Share (%), Market Size (USD Billion)}
  • Europe (The U.K., Germany, France, Italy, Spain, Poland, Sweden & RoE)  Genome Editing/Genome Engineering Market {Market Share (%), Market Size (USD Billion)}
  • Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest of Asia)  Genome Editing/Genome Engineering Market {Market Share (%), Market Size (USD Billion)}
  • Middle East & Africa (GCC, South Africa, North Africa, RoMEA)  Genome Editing/Genome Engineering Market {Market Share (%), Market Size (USD Billion)}

Based on technology, CRISPR accounted for the largest technology segment with the market share of 45% in the genome editing/genome engineering market in 2017 with its ability to perform multiplexible genome targeting in many species that were intractable using old genetic perturbation techniques. While on the basis of application, cell line technology is leading the genome editing market due to its implications while studying loss or gain of function mutations at the endogenous level and identifies responsive or resistant patient populations in a human cell line model.

Genome Editing Industry Trends & Outlook

According to our global market study on the basis of extensive primary and secondary research: “One trend is the ability of genome editing/genome engineering to cost-effectively produce biotherapeutics. In turn, that would make not only existing therapies more affordable, but it would allow small production runs to work toward the realization of personalized medicine.”

Based on geography, North America accounted for the largest share of the overall genome editing/genome engineering market in 2017 at over 35.25% owing to increasing use of genetically modified crops, the development of gene therapy in the US, rising prevalence of infectious diseases and cancer, and rising availability of research grants and funding. While APAC is expected to witness the most significant development owing to strengthening economies of developing countries such as India and China and the increased focus of the respective governments on encouraging research in the field of genomics, in addition, China hosts the world’s largest genomic research institute, the Beijing Genomics Institute in order to sustain the growth of genome editing/genome engineering market. Europe genome editing/genome engineering market will grow at the substantial rate due to the ample amount of funds and presence of companies undertaking research in the field of genomics.         

Market Growth Drivers & Market Restraints

According to the report, major driving factor is the adoption of genome editing/genome engineering for cell line engineering, genetic engineering, diagnostics and therapeutics.  For instance, genome editing is used in target gene modification in plants and eradication of vector borne diseases such as yellow fever, dengue, Zika, West Nile, Schistomiasis, Leishmaniasis and Lymes disease which is the segment that is attracting major portion of investments in agricultural and healthcare sector.  

Further, the report states the biggest challenge is the complex nature of the drugs coupled with high development costs, sub-optimal development framework and inter-patient variability of effects contributing to potential barriers that are integrating genome editing/genome engineering into underserved medical settings.  

Covered In This Genome Editing/Genome Engineering Market Report                                                                                                                  

The report covers the present ground scenario and the future growth prospects of the Genome Editing/Genome Engineering market for 2017-2030 along with the data of research and development projects on genome editing coupled with the investments and organizations involved worldwide. We calculated the market size and revenue share on the basis of revenue generated from major players across the globe. The Genome Editing/Genome Engineering market is forecasted on the basis of revenue analysis, product benchmarking and strategic developments of key market players. The report also includes micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Global Genome Editing/Genome Engineering Market Outlook 2017-2030, has been prepared based on an in-depth market analysis from industry experts. The report covers the competitive landscape and current position of major players in the global Genome Editing/Genome Engineering market. The report also includes porter’s five force model, SWOT analysis, company profiling, business strategies of market players and their business models. Global Genome Editing/Genome Engineering market report also recognizes value chain analysis to understand the cost differentiation to provide competitive advantage to the existing and new entry players.

Key Market Players

Our global Genome Editing/Genome Engineering market report comprises of the following companies as the key players:

  • Horizon Discovery Group plc
  •  Thermo Fisher Scientific
  •  Merck
  •  Horizon Discovery Group
  •  GenScript
  •  Sangamo BioSciences
  •  Integrated DNA Technologies
  •  Lonza Group
  •  New England Biolabs
  •  OriGene Technologies
  •  Transposagen Biopharmaceuticals
  •  Editas Medicine
  •  CRISPR Therapeutics.

 The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

For a full detailed overview, send us the sample request.

Key questions answered in this Genome Editing/Genome Engineering Market Report

  • What is the total market size by 2030 and what would be the expected growth rate of market?
  • What is the revenue of total market in 2016-17 and what would be the expected demand over the forecast period?
  • What are the key market trends?
  • What are the factors which are driving this market?
  • What are the major barriers to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities for the existing and entry level players?
  • What are the recent developments and business strategy of the key players?

We can provide two hour complimentary interaction with our analyst after the purchase of this market report. Details are imparted within the report.

{ }

Global Genome Editing/Genome Engineering Market Size, Trends, Share, Market Segmentation By Intended Audience & by Region with Forecast 2017-2030

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

OR Call Us:+1-646-568-7747

Table of Contents

Please Select Linenece Type